Automated pumps are already used by about 40% of those with the autoimmune version of diabetes, known as Type-1.
Novo Nordisk (NVO) plans to invest $4.1 billion in order to expand its Clayton facility with a second manufacturing plant, boosting capacity for injectable treatments and creating 1,000 new jobs.
Assuming the rosier expectations will positively unfold, a reality check is done to compare the current valuation to informative financial ratios